These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 8612238)
1. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Pai LH; Wittes R; Setser A; Willingham MC; Pastan I Nat Med; 1996 Mar; 2(3):350-3. PubMed ID: 8612238 [TBL] [Abstract][Full Text] [Related]
2. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Kuan CT; Pai LH; Pastan I Clin Cancer Res; 1995 Dec; 1(12):1589-94. PubMed ID: 9815960 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Bigner DD; Archer GE; McLendon RE; Friedman HS; Fuchs HE; Pai LH; Herndon JE; Pastan IH Clin Cancer Res; 1995 Dec; 1(12):1545-55. PubMed ID: 9815955 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422 [TBL] [Abstract][Full Text] [Related]
6. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Pastan IH; Archer GE; McLendon RE; Friedman HS; Fuchs HE; Wang QC; Pai LH; Herndon J; Bigner DD Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2765-9. PubMed ID: 7708720 [TBL] [Abstract][Full Text] [Related]
8. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. Siegall CB Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. Onda M; Willingham M; Wang QC; Kreitman RJ; Tsutsumi Y; Nagata S; Pastan I J Immunol; 2000 Dec; 165(12):7150-6. PubMed ID: 11120846 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049 [TBL] [Abstract][Full Text] [Related]
11. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047 [TBL] [Abstract][Full Text] [Related]
13. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Hassan R; Williams-Gould J; Watson T; Pai-Scherf L; Pastan I Clin Cancer Res; 2004 Jan; 10(1 Pt 1):16-8. PubMed ID: 14734446 [TBL] [Abstract][Full Text] [Related]
14. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability. Bera TK; Pastan I Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Bera TK; Viner J; Brinkmann E; Pastan I Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601 [TBL] [Abstract][Full Text] [Related]
17. Clinical trials with Pseudomonas exotoxin immunotoxins. Pai LH; Pastan I Curr Top Microbiol Immunol; 1998; 234():83-96. PubMed ID: 9670614 [No Abstract] [Full Text] [Related]
18. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. Shancer Z; Liu XF; Nagata S; Zhou Q; Bera TK; Pastan I Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4592-4598. PubMed ID: 30782819 [TBL] [Abstract][Full Text] [Related]
19. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Shinohara H; Fan D; Ozawa S; Yano S; Van Arsdell M; Viner JL; Beers R; Pastan I; Fidler IJ Int J Oncol; 2000 Oct; 17(4):643-51. PubMed ID: 10995873 [TBL] [Abstract][Full Text] [Related]